Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Wegovy is produced by pharmaceutical company Novo Nordisk. Weight-loss drug makers are directly targeting employers in a ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Lilly and Pfizer ... Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

HHS houses major health agencies in the U.S., like the FDA, the CDC and the NIH, and it’s also responsible for Medicare and ...

Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...